Skip to content

Zevra Therapeutics, Inc. ZVRA Net Investment in Lease

Net Investment in Lease at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
Theravance Biopharma logo
Theravance BiopharmaTBPH
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
PVL
Palvella TherapeuticsPVLA
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s net investment in lease?
Zevra Therapeutics, Inc. (ZVRA) reported net investment in lease of $1.09M in Q1 2026.
How has Zevra Therapeutics, Inc.'s net investment in lease changed year-over-year?
Zevra Therapeutics, Inc.'s net investment in lease decreased by 33.6% year-over-year, from $1.64M to $1.09M.
What is the long-term trend for Zevra Therapeutics, Inc.'s net investment in lease?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s net investment in lease has grown at a -2.1% compound annual growth rate (CAGR), from $1.35M to $1.21M.